Cargando…
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, sy...
Autores principales: | Phan, Alexander T, Gukasyan, Janet, Arabian, Sarkis, Wang, Sharon, Neeki, Michael M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235874/ https://www.ncbi.nlm.nih.gov/pubmed/34194882 http://dx.doi.org/10.7759/cureus.15280 |
Ejemplares similares
-
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022) -
Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022) -
Left-Sided Transudative Chylothorax With Concomitant Chylous Ascites in the Setting of Liver Cirrhosis
por: Gukasyan, Janet, et al.
Publicado: (2023) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022)